title: DNA Adducts from Anticancer Drugs as Candidate Predictive Markers for Precision Medicine.
abstract: Biomarker-driven drug selection plays a central role in cancer drug discovery and development, and in diagnostic strategies to improve the use of traditional chemotherapeutic drugs. DNA-modifying anticancer drugs are still used as first line medication, but drawbacks such as resistance and side effects remain an issue. Monitoring the formation and level of DNA modifications induced by anticancer drugs is a potential strategy for stratifying patients and predicting drug efficacy. In this perspective, preclinical and clinical data concerning the relationship between drug-induced DNA adducts and biological response for platinum drugs and combination therapies, nitrogen mustards and half-mustards, hypoxia-activated drugs, reductase-activated drugs, and minor groove binding agents are presented and discussed. Aspects including measurement strategies, identification of adducts, and biological factors that influence the predictive relationship between DNA modification and biological response are addressed. A positive correlation between DNA adduct levels and response was observed for the majority of the studies, demonstrating the high potential of using DNA adducts from anticancer drugs as mechanism-based biomarkers of susceptibility, especially as bioanalysis approaches with higher sensitivity and throughput emerge.
authors.affiliation: Department of Health Sciences and Technology, ETH Zurich , Schmelzbergstrasse 9, 8092 Zurich, Switzerland.
authors.forename: Alessia
authors.identifier: 0000-0002-8287-9551
authors.initials: A
authors.lastname: Stornetta
authors.affiliation: Department of Internal Medicine, Division of Hematology and Oncology and the UC Davis Comprehensive Cancer Center, University of California Davis , 4501 X Street, Sacramento, California 95655, United States.|Accelerated Medical Diagnostics, Inc. , 2121 Second Street, B101, Davis, California 95618, United States.
authors.forename: Maike
authors.initials: M
authors.lastname: Zimmermann
authors.affiliation: Accelerated Medical Diagnostics, Inc. , 2121 Second Street, B101, Davis, California 95618, United States.
authors.forename: George D
authors.initials: GD
authors.lastname: Cimino
authors.affiliation: Department of Internal Medicine, Division of Hematology and Oncology and the UC Davis Comprehensive Cancer Center, University of California Davis , 4501 X Street, Sacramento, California 95655, United States.|Accelerated Medical Diagnostics, Inc. , 2121 Second Street, B101, Davis, California 95618, United States.
authors.forename: Paul T
authors.initials: PT
authors.lastname: Henderson
authors.affiliation: Department of Health Sciences and Technology, ETH Zurich , Schmelzbergstrasse 9, 8092 Zurich, Switzerland.
authors.forename: Shana J
authors.initials: SJ
authors.lastname: Sturla
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D015415:Biomarkers / Q000378:metabolism; D018736:DNA Adducts / Q000378:metabolism*; D006801:Humans; D000860:Hypoxia / Q000378:metabolism; D009588:Nitrogen Mustard Compounds / Q000627:therapeutic use; D010088:Oxidoreductases / Q000378:metabolism; D017671:Platinum Compounds / Q000627:therapeutic use; D057285:Precision Medicine; D011355:Prodrugs / Q000494:pharmacology
chemical_list: D000970:Antineoplastic Agents; D015415:Biomarkers; D018736:DNA Adducts; D009588:Nitrogen Mustard Compounds; D017671:Platinum Compounds; D011355:Prodrugs; D010088:Oxidoreductases